A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways
DSpace/Manakin Repository
A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways
| Title: | A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways |
| Author: |
Spring, Bryan Q.; Sears, R. Bryan; Zheng, Lei Zak; Mai, Zhiming; Watanabe, Reika; Sherwood, Margaret E.; Schoenfeld, David A.; Pogue, Brian W.; Pereira, Stephen P.; Villa, Elizabeth; Hasan, Tayyaba
Note: Order does not necessarily reflect citation order of authors. |
| Citation: | Spring, B. Q., R. B. Sears, L. Z. Zheng, Z. Mai, R. Watanabe, M. E. Sherwood, D. A. Schoenfeld, et al. 2015. “A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways.” Nature nanotechnology 11 (4): 378-387. doi:10.1038/nnano.2015.311. http://dx.doi.org/10.1038/nnano.2015.311. |
| Full Text & Related Files: |
4821671.pdf (2.299Mb; PDF) 
|
| Abstract: | Nanoscale drug delivery vehicles can facilitate multimodal therapies of cancer by promoting tumour-selective drug release. However, few are effective because cancer cells develop ways to resist and evade treatment. Here, we introduce a photoactivatable multi-inhibitor nanoliposome (PMIL) that imparts light-induced cytotoxicity in synchrony with photo-initiated and sustained release of inhibitors that suppress tumour regrowth and treatment escape signalling pathways. The PMIL consists of a nanoliposome doped with a photoactivatable chromophore (benzoporphyrin derivative, BPD) in the lipid bilayer, and a nanoparticle containing cabozantinib (XL184)—a multikinase inhibitor—encapsulated inside. Near infrared tumour irradiation, following intravenous PMIL administration, triggers photodynamic damage of tumour cells and microvessels, and simultaneously initiates release of XL184 inside the tumour. A single PMIL treatment achieves prolonged tumour reduction in two mouse models and suppresses metastatic escape in an orthotopic pancreatic tumour model. The PMIL offers new prospects for cancer therapy by enabling spatiotemporal control of drug release whilst reducing systemic drug exposure and associated toxicities. |
| Published Version: | doi:10.1038/nnano.2015.311 |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821671/pdf/ |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822396 |
| Downloads of this work: |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [20563]
-
SPH Scholarly Articles [6055]
Contact administrator regarding this item (to report mistakes or request changes)
